Table 1.
Patient characteristics of the study population in the primary analysis
| Patient characteristics before PSW | Patient characteristics (%) after PSWa | |||||
|---|---|---|---|---|---|---|
| CCT (n = 103) | Without CCT (n = 265) | Standardized differenceb | CCT | Without CCT | Standardized differenceb | |
| Number (%)b or mean (SD)b | Number (%)b or mean (SD)b | |||||
| Age (years) | ||||||
| ≤ 58 | 53 (51) | 139 (52) | 0.020 | 50 | 50 | ≈ 0 |
| > 58 | 50 (49) | 126 (48) | 50 | 50 | ||
| Gender | ||||||
| Female | 5 (5) | 12 (5) | 0.015 | 5 | 5 | ≈ 0 |
| Male | 98 (95) | 253 (95) | 95 | 95 | ||
| Residency | ||||||
| Non-north | 77 (75) | 185 (70) | 0.111 | 73 | 73 | ≈ 0 |
| North | 26 (25) | 80 (30) | 27 | 27 | ||
| Comorbidity | ||||||
| Without | 91 (88) | 233 (88) | 0.013 | 89 | 89 | ≈ 0 |
| Withc | 12 (12) | 32 (12) | 11 | 11 | ||
| BMI (kg/m2) | ||||||
| ≤ 18.5 | 22 (21) | 62 (23) | 0.049 | 21 | 21 | ≈ 0 |
| > 18.5 | 81 (79) | 203 (77) | 79 | 79 | ||
| Drinking | ||||||
| No | 14 (14) | 46 (17) | 0.104 | 14 | 14 | ≈ 0 |
| Yes | 89 (86) | 219 (83) | 86 | 86 | ||
| Smoking | ||||||
| No | 10 (10) | 43 (16) | 0.195 | 11 | 11 | ≈ 0 |
| Yes | 93 (90) | 222 (84) | 89 | 89 | ||
| Grade | ||||||
| Poorly | 34 (33) | 59 (22) | 0.242 | 30 | 30 | ≈ 0 |
| Well/moderately differentiated | 69 (67) | 206 (78) | 70 | 70 | ||
| Tumor location | ||||||
| Upper | 56 (54) | 97 (37) | 50 | 50 | ||
| Middle | 34 (33) | 122 (46) | 0.269 | 36 | 36 | ≈ 0 |
| Lower | 13 (13) | 46 (17) | 0.133 | 14 | 14 | ≈ 0 |
| Tumor size (cm) | ||||||
| ≤ 5 cm | 43 (42) | 99 (37) | 0.090 | 41 | 41 | ≈ 0 |
| > 5 cm | 60 (58) | 166 (63) | 59 | 59 | ||
| Clinical T-stage | ||||||
| T1–T2 | 10 (10) | 32 (12) | 0.076 | 10 | 10 | ≈ 0 |
| T3–T4 | 93 (90) | 233 (88) | 90 | 90 | ||
| Clinical N-stage | ||||||
| N0 | 9 (9) | 23 (9) | 0.002 | 9 | 9 | ≈ 0 |
| N1-N2 | 94 (91) | 242 (91) | 91 | 91 | ||
| Clinical stage | ||||||
| II | 11 (11) | 30 (11) | 0.020 | 12 | 12 | ≈ 0 |
| III | 92 (89) | 235 (89) | 88 | 88 | ||
| Reason for no surgery | ||||||
| Without contraindication | 99 (96) | 248 (94) | 0.115 | 95 | 95 | ≈ 0 |
| With contraindication | 4 (4) | 17 (6) | 5 | 5 | ||
| RT modality | ||||||
| 3DCRT | 7 (7) | 7 (3) | 0.197 | 5 | 5 | ≈ 0 |
| IMRT | 96 (93) | 258 (97) | 95 | 95 | ||
| Use of PET | ||||||
| No | 45 (44) | 77 (29) | 0.308 | 37 | 37 | ≈ 0 |
| Yes | 58 (56) | 188 (71) | 63 | 63 | ||
| RT break | ||||||
| ≤ 1 week | 79 (77) | 197 (74) | 0.055 | 76 | 76 | ≈ 0 |
| > 1 week | 24 (23) | 68 (26) | 24 | 24 | ||
| RT dose | ||||||
| Low | 25 (24) | 88 (33) | 0.198 | 26 | 26 | ≈ 0 |
| High | 78 (76) | 177 (67) | 74 | 74 | ||
| Induction chemotherapy | ||||||
| Without | 98 (95) | 258 (97) | 0.117 | 96 | 96 | ≈ 0 |
| With | 5 (5) | 7 (3) | 4 | 4 | ||
3DCRT, three-dimensional radiotherapy; BMI, Body Mass Index; CCT, consolidative chemotherapy; IGRT, image-guided radiotherapy; IMRT, intensity-modulated radiotherapy; PET, positron emission tomography; PSW, Propensity Score (PS) Weighting; RT, radiotherapy; SD, standard deviation
aWeighted proportion for each group
bRounded
cModified Carlson comorbidity score ≥ 1